Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

NCT: NCT07504796 · RECRUITING

NCT IDNCT07504796
StatusRECRUITING
Start Date2026-04-13
Completion2031-05

Brief Summary

The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.

Frequently Asked Questions

What is ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab?

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab is a clinical trial registered under NCT07504796. Current status: RECRUITING.

What is the status of NCT07504796?

The current status of NCT07504796 (ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab) is: RECRUITING.

When did ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab start?

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab started on 2026-04-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑